Despite $2B Deal, J&J's Risperdal Fight Rages On In Pa.

Law360, Philadelphia (November 8, 2013, 7:24 PM EST) -- Johnson & Johnson’s blockbuster $2.2 billion Risperdal settlement resolves off-label marketing claims over the anti-psychotic drug, but it will have little effect on product liability litigation in Pennsylvania, where plaintiffs attorneys expect the drugmaker to continue the fight against claims that the drug caused health problems in teenage boys.

The founding partner of Sheller PC, a firm representing plaintiffs in nearly 250 product liability cases pending in the Philadelphia Court of Common Pleas, said that he will be unable to use a guilty plea by J&J...
To view the full article, register now.